Effects of Yohimbine on plasma catecholamine levels in orthostatic hypotension related to Pakinson disease or multiple system atrophy
Identifieur interne : 001A50 ( PascalFrancis/Corpus ); précédent : 001A49; suivant : 001A51Effects of Yohimbine on plasma catecholamine levels in orthostatic hypotension related to Pakinson disease or multiple system atrophy
Auteurs : J. M. Senard ; O. Rascol ; G. Durrieu ; M. A. Tran ; M. Berlan ; A. Rascol ; J. L. MontastrucSource :
- Clinical neuropharmacology [ 0362-5664 ] ; 1993.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
|
---|
Format Inist (serveur)
NO : | PASCAL 93-0406320 INIST |
---|---|
ET : | Effects of Yohimbine on plasma catecholamine levels in orthostatic hypotension related to Pakinson disease or multiple system atrophy |
AU : | SENARD (J. M.); RASCOL (O.); DURRIEU (G.); TRAN (M. A.); BERLAN (M.); RASCOL (A.); MONTASTRUC (J. L.) |
AF : | INSERM CHU Purpan, fac. médecine, lab. pharmacologie médicale clin./31073 Toulouse/France (1 aut., 2 aut., 3 aut., 4 aut., 5 aut.) |
DT : | Publication en série; Courte communication, note brève; Niveau analytique |
SO : | Clinical neuropharmacology; ISSN 0362-5664; Coden CLNEDB; Etats-Unis; Da. 1993; Vol. 16; No. 1; Pp. 70-76; Bibl. 20 ref. |
LA : | Anglais |
CC : | 002B02F09 |
FD : | Bloquant α-adrénergique; Mécanisme action; Homme; Voie orale; Catécholamine; Hypotension artérielle orthostatique; Parkinson maladie; Dégénérescence neuronale présénile Shy Drager; Hypertenseur; Yohimbine |
FG : | Appareil circulatoire pathologie; Système nerveux pathologie; Maladie dégénérative; Système nerveux sympathique pathologie |
ED : | Alpha blocking agent; Mechanism of action; Human; Oral administration; Catecholamine; Postural hypotension; Parkinson disease; Shy Drager presenile neuronal degeneration; Hypertensive drug |
EG : | Cardiovascular disease; Nervous system diseases; Degenerative disease; Autonomic neuropathy |
SD : | Bloqueador α-adrenérgico; Mecanismo acción; Hombre; Vía oral; Catecolamina; Hipotensión arterial ortostática; Parkinson enfermedad; Degeneración neuronal presenil Shy Drager; Hipertensor |
LO : | INIST-16720.354000038534060080 |
ID : | 93-0406320 |
Links to Exploration step
Pascal:93-0406320Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Effects of Yohimbine on plasma catecholamine levels in orthostatic hypotension related to Pakinson disease or multiple system atrophy</title>
<author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J. M." last="Senard">J. M. Senard</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM CHU Purpan, fac. médecine, lab. pharmacologie médicale clin.</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM CHU Purpan, fac. médecine, lab. pharmacologie médicale clin.</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Durrieu, G" sort="Durrieu, G" uniqKey="Durrieu G" first="G." last="Durrieu">G. Durrieu</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM CHU Purpan, fac. médecine, lab. pharmacologie médicale clin.</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tran, M A" sort="Tran, M A" uniqKey="Tran M" first="M. A." last="Tran">M. A. Tran</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM CHU Purpan, fac. médecine, lab. pharmacologie médicale clin.</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Berlan, M" sort="Berlan, M" uniqKey="Berlan M" first="M." last="Berlan">M. Berlan</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM CHU Purpan, fac. médecine, lab. pharmacologie médicale clin.</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A." last="Rascol">A. Rascol</name>
</author>
<author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J. L." last="Montastruc">J. L. Montastruc</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">93-0406320</idno>
<date when="1993">1993</date>
<idno type="stanalyst">PASCAL 93-0406320 INIST</idno>
<idno type="RBID">Pascal:93-0406320</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001A50</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Effects of Yohimbine on plasma catecholamine levels in orthostatic hypotension related to Pakinson disease or multiple system atrophy</title>
<author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J. M." last="Senard">J. M. Senard</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM CHU Purpan, fac. médecine, lab. pharmacologie médicale clin.</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM CHU Purpan, fac. médecine, lab. pharmacologie médicale clin.</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Durrieu, G" sort="Durrieu, G" uniqKey="Durrieu G" first="G." last="Durrieu">G. Durrieu</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM CHU Purpan, fac. médecine, lab. pharmacologie médicale clin.</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tran, M A" sort="Tran, M A" uniqKey="Tran M" first="M. A." last="Tran">M. A. Tran</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM CHU Purpan, fac. médecine, lab. pharmacologie médicale clin.</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Berlan, M" sort="Berlan, M" uniqKey="Berlan M" first="M." last="Berlan">M. Berlan</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM CHU Purpan, fac. médecine, lab. pharmacologie médicale clin.</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A." last="Rascol">A. Rascol</name>
</author>
<author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J. L." last="Montastruc">J. L. Montastruc</name>
</author>
</analytic>
<series><title level="j" type="main">Clinical neuropharmacology</title>
<title level="j" type="abbreviated">Clin. neuropharmacol.</title>
<idno type="ISSN">0362-5664</idno>
<imprint><date when="1993">1993</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Clinical neuropharmacology</title>
<title level="j" type="abbreviated">Clin. neuropharmacol.</title>
<idno type="ISSN">0362-5664</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alpha blocking agent</term>
<term>Catecholamine</term>
<term>Human</term>
<term>Hypertensive drug</term>
<term>Mechanism of action</term>
<term>Oral administration</term>
<term>Parkinson disease</term>
<term>Postural hypotension</term>
<term>Shy Drager presenile neuronal degeneration</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Bloquant α-adrénergique</term>
<term>Mécanisme action</term>
<term>Homme</term>
<term>Voie orale</term>
<term>Catécholamine</term>
<term>Hypotension artérielle orthostatique</term>
<term>Parkinson maladie</term>
<term>Dégénérescence neuronale présénile Shy Drager</term>
<term>Hypertenseur</term>
<term>Yohimbine</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0362-5664</s0>
</fA01>
<fA02 i1="01"><s0>CLNEDB</s0>
</fA02>
<fA03 i2="1"><s0>Clin. neuropharmacol.</s0>
</fA03>
<fA05><s2>16</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Effects of Yohimbine on plasma catecholamine levels in orthostatic hypotension related to Pakinson disease or multiple system atrophy</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>SENARD (J. M.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>RASCOL (O.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>DURRIEU (G.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>TRAN (M. A.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>BERLAN (M.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>RASCOL (A.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>MONTASTRUC (J. L.)</s1>
</fA11>
<fA14 i1="01"><s1>INSERM CHU Purpan, fac. médecine, lab. pharmacologie médicale clin.</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>70-76</s1>
</fA20>
<fA21><s1>1993</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>16720</s2>
<s5>354000038534060080</s5>
</fA43>
<fA44><s0>0000</s0>
</fA44>
<fA45><s0>20 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>93-0406320</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i2="1"><s0>Clinical neuropharmacology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X"><s0>002B02F09</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Bloquant α-adrénergique</s0>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Alpha blocking agent</s0>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Bloqueador α-adrenérgico</s0>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Mécanisme action</s0>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Mechanism of action</s0>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Mecanismo acción</s0>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Homme</s0>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Human</s0>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Hombre</s0>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Voie orale</s0>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Oral administration</s0>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Vía oral</s0>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Catécholamine</s0>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Catecholamine</s0>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Catecolamina</s0>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Hypotension artérielle orthostatique</s0>
<s2>NM</s2>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Postural hypotension</s0>
<s2>NM</s2>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Hipotensión arterial ortostática</s0>
<s2>NM</s2>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s2>NM</s2>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Dégénérescence neuronale présénile Shy Drager</s0>
<s2>NM</s2>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Shy Drager presenile neuronal degeneration</s0>
<s2>NM</s2>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Degeneración neuronal presenil Shy Drager</s0>
<s2>NM</s2>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Hypertenseur</s0>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Hypertensive drug</s0>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Hipertensor</s0>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Yohimbine</s0>
<s2>FR</s2>
<s4>INC</s4>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Appareil circulatoire pathologie</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cardiovascular disease</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux sympathique pathologie</s0>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Autonomic neuropathy</s0>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervioso simpático patología</s0>
</fC07>
<fN21><s1>161</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 93-0406320 INIST</NO>
<ET>Effects of Yohimbine on plasma catecholamine levels in orthostatic hypotension related to Pakinson disease or multiple system atrophy</ET>
<AU>SENARD (J. M.); RASCOL (O.); DURRIEU (G.); TRAN (M. A.); BERLAN (M.); RASCOL (A.); MONTASTRUC (J. L.)</AU>
<AF>INSERM CHU Purpan, fac. médecine, lab. pharmacologie médicale clin./31073 Toulouse/France (1 aut., 2 aut., 3 aut., 4 aut., 5 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Clinical neuropharmacology; ISSN 0362-5664; Coden CLNEDB; Etats-Unis; Da. 1993; Vol. 16; No. 1; Pp. 70-76; Bibl. 20 ref.</SO>
<LA>Anglais</LA>
<CC>002B02F09</CC>
<FD>Bloquant α-adrénergique; Mécanisme action; Homme; Voie orale; Catécholamine; Hypotension artérielle orthostatique; Parkinson maladie; Dégénérescence neuronale présénile Shy Drager; Hypertenseur; Yohimbine</FD>
<FG>Appareil circulatoire pathologie; Système nerveux pathologie; Maladie dégénérative; Système nerveux sympathique pathologie</FG>
<ED>Alpha blocking agent; Mechanism of action; Human; Oral administration; Catecholamine; Postural hypotension; Parkinson disease; Shy Drager presenile neuronal degeneration; Hypertensive drug</ED>
<EG>Cardiovascular disease; Nervous system diseases; Degenerative disease; Autonomic neuropathy</EG>
<SD>Bloqueador α-adrenérgico; Mecanismo acción; Hombre; Vía oral; Catecolamina; Hipotensión arterial ortostática; Parkinson enfermedad; Degeneración neuronal presenil Shy Drager; Hipertensor</SD>
<LO>INIST-16720.354000038534060080</LO>
<ID>93-0406320</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A50 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001A50 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= PascalFrancis |étape= Corpus |type= RBID |clé= Pascal:93-0406320 |texte= Effects of Yohimbine on plasma catecholamine levels in orthostatic hypotension related to Pakinson disease or multiple system atrophy }}
![]() | This area was generated with Dilib version V0.6.29. | ![]() |